[
  {
    "ts": null,
    "headline": "AbbVie to invest $195 million in North Chicago facility that will produce active pharmaceutical ingredients",
    "summary": "Pharmaceutical company AbbVie announced Tuesday that it will construct a new $195 million facility near its headquarters in North Chicago, Illinois. AbbvVie is one of the largest biomedical companies in the world, ranking just below Pfizer in revenue. The company is known for its production of Humira, a treatment for autoimmune diseases such as rheumatoid arthritis and Crohn’s, and Botox. The ...",
    "url": "https://finnhub.io/api/news?id=745bb827fe673cde00141841e0b984a262f0952485492642e296bc0d7cabad8f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755031560,
      "headline": "AbbVie to invest $195 million in North Chicago facility that will produce active pharmaceutical ingredients",
      "id": 136328255,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pharmaceutical company AbbVie announced Tuesday that it will construct a new $195 million facility near its headquarters in North Chicago, Illinois. AbbvVie is one of the largest biomedical companies in the world, ranking just below Pfizer in revenue. The company is known for its production of Humira, a treatment for autoimmune diseases such as rheumatoid arthritis and Crohn’s, and Botox. The ...",
      "url": "https://finnhub.io/api/news?id=745bb827fe673cde00141841e0b984a262f0952485492642e296bc0d7cabad8f"
    }
  },
  {
    "ts": null,
    "headline": "Industry Leader in Lyophilization, Dr. Serguei Tchessalov, Partners with BioTechnique® to Enhance Customer Capabilities",
    "summary": "YORK, Pa., August 12, 2025--BioTechnique® LLC (\"BioTechnique\" or the \"Company\") proudly welcomes Dr. Serguei Tchessalov, a globally recognized subject matter expert in lyophilization, whose decades of experience in formulation development, process design, and scale-up bring invaluable insight to clients navigating complex biologic and vaccine manufacturing. With over 40 years of experience spanning both Russia and the United States, Dr. Tchessalov brings deep expertise in the formulation and fre",
    "url": "https://finnhub.io/api/news?id=814f7cfc8ccad44d28389089aa5ae434453c5cf879cd550b88696b2ed75de88f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755030540,
      "headline": "Industry Leader in Lyophilization, Dr. Serguei Tchessalov, Partners with BioTechnique® to Enhance Customer Capabilities",
      "id": 136323071,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "YORK, Pa., August 12, 2025--BioTechnique® LLC (\"BioTechnique\" or the \"Company\") proudly welcomes Dr. Serguei Tchessalov, a globally recognized subject matter expert in lyophilization, whose decades of experience in formulation development, process design, and scale-up bring invaluable insight to clients navigating complex biologic and vaccine manufacturing. With over 40 years of experience spanning both Russia and the United States, Dr. Tchessalov brings deep expertise in the formulation and fre",
      "url": "https://finnhub.io/api/news?id=814f7cfc8ccad44d28389089aa5ae434453c5cf879cd550b88696b2ed75de88f"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Advance in Afternoon Trading",
    "summary": "Health care stocks rose Tuesday afternoon, with the NYSE Health Care Index up 0.3% and the Health Ca",
    "url": "https://finnhub.io/api/news?id=44898670113173f3eb11866417ec12fa9fc2e67d687993d71e9d0fda80d82bb4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755021194,
      "headline": "Sector Update: Health Care Stocks Advance in Afternoon Trading",
      "id": 136322973,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Health care stocks rose Tuesday afternoon, with the NYSE Health Care Index up 0.3% and the Health Ca",
      "url": "https://finnhub.io/api/news?id=44898670113173f3eb11866417ec12fa9fc2e67d687993d71e9d0fda80d82bb4"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (PFE) Reports Positive Phase 3 Results In Bladder Cancer Treatment Study",
    "summary": "Pfizer (PFE) recently announced positive results from its Phase 3 EV-303 clinical trial in collaboration with Astellas Pharma, showing significant improvements in event-free and overall survival for bladder cancer patients, a development that showcases the company's ongoing commitment to oncological advancements. This announcement, among other positive updates like the FDA's acceptance of the NDA for Vepdegestrant, likely contributed to Pfizer’s 7.48% price increase over the last quarter,...",
    "url": "https://finnhub.io/api/news?id=bfebd0efd179940dadf87b57e531a8d51a16592d887cd213b09263ea868d7326",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755019990,
      "headline": "Pfizer (PFE) Reports Positive Phase 3 Results In Bladder Cancer Treatment Study",
      "id": 136320703,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) recently announced positive results from its Phase 3 EV-303 clinical trial in collaboration with Astellas Pharma, showing significant improvements in event-free and overall survival for bladder cancer patients, a development that showcases the company's ongoing commitment to oncological advancements. This announcement, among other positive updates like the FDA's acceptance of the NDA for Vepdegestrant, likely contributed to Pfizer’s 7.48% price increase over the last quarter,...",
      "url": "https://finnhub.io/api/news?id=bfebd0efd179940dadf87b57e531a8d51a16592d887cd213b09263ea868d7326"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Raises Its Guidance and Analysts Up Their Targets - PFE Stock Looks Cheap",
    "summary": "Pfizer stock is incredibly cheap following management's raise of its 2025 adjusted earnings per share guidance. It's at just over 8x this year's estimates and 7.8x next year. That's too cheap. Shorting puts works here.",
    "url": "https://finnhub.io/api/news?id=aab6e600d69197906c62f24023c238ee248c3666ccb22b2c00f7b3189a8b8335",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755019275,
      "headline": "Pfizer Raises Its Guidance and Analysts Up Their Targets - PFE Stock Looks Cheap",
      "id": 136320704,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer stock is incredibly cheap following management's raise of its 2025 adjusted earnings per share guidance. It's at just over 8x this year's estimates and 7.8x next year. That's too cheap. Shorting puts works here.",
      "url": "https://finnhub.io/api/news?id=aab6e600d69197906c62f24023c238ee248c3666ccb22b2c00f7b3189a8b8335"
    }
  },
  {
    "ts": null,
    "headline": "Perioperative Padcev and Keytruda improves survival in MIBC",
    "summary": "In the Phase III trial, the combination improved event-free survival and overall survival.",
    "url": "https://finnhub.io/api/news?id=baf9066a6718b608fcbe28608089e0041ab58e84a9b52514af373a34b778d53a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755013668,
      "headline": "Perioperative Padcev and Keytruda improves survival in MIBC",
      "id": 136320221,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "In the Phase III trial, the combination improved event-free survival and overall survival.",
      "url": "https://finnhub.io/api/news?id=baf9066a6718b608fcbe28608089e0041ab58e84a9b52514af373a34b778d53a"
    }
  },
  {
    "ts": null,
    "headline": "SMMT Q2 Loss Wider Than Expected, Ivonescimab Studies in Focus",
    "summary": "Summit Therapeutics posts wider-than-expected second-quarter loss as ivonescimab trials advance in multiple lung cancer settings.",
    "url": "https://finnhub.io/api/news?id=16584c7e63fc97a940909a82e17bc930b623d0b60616a2651204bdd401d7650f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755013380,
      "headline": "SMMT Q2 Loss Wider Than Expected, Ivonescimab Studies in Focus",
      "id": 136320222,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Summit Therapeutics posts wider-than-expected second-quarter loss as ivonescimab trials advance in multiple lung cancer settings.",
      "url": "https://finnhub.io/api/news?id=16584c7e63fc97a940909a82e17bc930b623d0b60616a2651204bdd401d7650f"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Pfizer, Novo Nordisk and Eli Lilly",
    "summary": "Pfizer beats Q2 estimates with rising oncology sales, new drug launches, and strong Seagen-driven portfolio growth.",
    "url": "https://finnhub.io/api/news?id=57ffee763b6320d47ff71751927d6f006b0b6b56a1e470cdfc257053fff5acb7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755011400,
      "headline": "The Zacks Analyst Blog Highlights Pfizer, Novo Nordisk and Eli Lilly",
      "id": 136320223,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer beats Q2 estimates with rising oncology sales, new drug launches, and strong Seagen-driven portfolio growth.",
      "url": "https://finnhub.io/api/news?id=57ffee763b6320d47ff71751927d6f006b0b6b56a1e470cdfc257053fff5acb7"
    }
  },
  {
    "ts": null,
    "headline": "Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients",
    "summary": "On Tuesday, Merck & Co. Inc. (NYSE:MRK) released topline results from the Phase 3 KEYNOTE-905 trial (also known as EV-303) in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy. In this study, Keytruda (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv), given before and after surgery (radical cystectomy), demonstrated a statistically significant and clinically meaningful improvement in event-free survival (EFS), the study’s primary endpoint",
    "url": "https://finnhub.io/api/news?id=c726f113507eda77bf53434a0a9a19d38c4f234b54e5296b1b85e44c1d6751d4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755010019,
      "headline": "Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients",
      "id": 136320224,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "On Tuesday, Merck & Co. Inc. (NYSE:MRK) released topline results from the Phase 3 KEYNOTE-905 trial (also known as EV-303) in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy. In this study, Keytruda (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv), given before and after surgery (radical cystectomy), demonstrated a statistically significant and clinically meaningful improvement in event-free survival (EFS), the study’s primary endpoint",
      "url": "https://finnhub.io/api/news?id=c726f113507eda77bf53434a0a9a19d38c4f234b54e5296b1b85e44c1d6751d4"
    }
  },
  {
    "ts": null,
    "headline": "Former Pfizer Chief Scientific Officer joins MC Sciences as Independent Chairman",
    "summary": "MC Sciences, an emerging biotech developing first-in-class novel therapeutics backed by ROC Venture Group, proudly announces the appointment of Dr. Mikael Dolsten, former Worldwide Chief Scientific Officer and President of Pfizer Research & Development, as Independent Chairman of the Board. In this role, he will help advance the company's mission of developing transformative and superior therapeutics targeting and controlling mast cells across multiple high-need disease indications, and progress",
    "url": "https://finnhub.io/api/news?id=e1ccabd77be1e044fad8023ad6b17165eae0df32b7fe79d9e3c507041c3f2f15",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755007200,
      "headline": "Former Pfizer Chief Scientific Officer joins MC Sciences as Independent Chairman",
      "id": 136320225,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "MC Sciences, an emerging biotech developing first-in-class novel therapeutics backed by ROC Venture Group, proudly announces the appointment of Dr. Mikael Dolsten, former Worldwide Chief Scientific Officer and President of Pfizer Research & Development, as Independent Chairman of the Board. In this role, he will help advance the company's mission of developing transformative and superior therapeutics targeting and controlling mast cells across multiple high-need disease indications, and progress",
      "url": "https://finnhub.io/api/news?id=e1ccabd77be1e044fad8023ad6b17165eae0df32b7fe79d9e3c507041c3f2f15"
    }
  },
  {
    "ts": null,
    "headline": "Statutory Profit Doesn't Reflect How Good Pfizer's (NYSE:PFE) Earnings Are",
    "summary": "NYSE:PFE 1 Year Share Price vs Fair Value Explore Pfizer's Fair Values from the Community and select yours Pfizer...",
    "url": "https://finnhub.io/api/news?id=4e71c05e2033b944559e6e7590c87eb6f7f1c2dc9d8b45e9173f01147e7e8a07",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755003115,
      "headline": "Statutory Profit Doesn't Reflect How Good Pfizer's (NYSE:PFE) Earnings Are",
      "id": 136320226,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NYSE:PFE 1 Year Share Price vs Fair Value Explore Pfizer's Fair Values from the Community and select yours Pfizer...",
      "url": "https://finnhub.io/api/news?id=4e71c05e2033b944559e6e7590c87eb6f7f1c2dc9d8b45e9173f01147e7e8a07"
    }
  },
  {
    "ts": null,
    "headline": "Multiple Myeloma Market Trends and Company Analysis Report 2025-2033 Featuring BMS, Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, and Takeda",
    "summary": "The Global Multiple Myeloma Market is projected to grow from USD 21.78 billion in 2024 to USD 40.41 billion by 2033, at a CAGR of 7.11%. Growth drivers include rising multiple myeloma cases, advances in targeted therapies like monoclonal antibodies, and the increasing adoption of immunotherapies. Enhanced diagnostics and greater healthcare accessibility are boosting market expansion. Key regions such as the U.S., Europe, and Asia-Pacific, are witnessing heightened therapy adoption. Challenges in",
    "url": "https://finnhub.io/api/news?id=935f341a4411b701496e42970e26df9cbaf2110b44122724cea5bef64808ce44",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754996340,
      "headline": "Multiple Myeloma Market Trends and Company Analysis Report 2025-2033 Featuring BMS, Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, and Takeda",
      "id": 136315997,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The Global Multiple Myeloma Market is projected to grow from USD 21.78 billion in 2024 to USD 40.41 billion by 2033, at a CAGR of 7.11%. Growth drivers include rising multiple myeloma cases, advances in targeted therapies like monoclonal antibodies, and the increasing adoption of immunotherapies. Enhanced diagnostics and greater healthcare accessibility are boosting market expansion. Key regions such as the U.S., Europe, and Asia-Pacific, are witnessing heightened therapy adoption. Challenges in",
      "url": "https://finnhub.io/api/news?id=935f341a4411b701496e42970e26df9cbaf2110b44122724cea5bef64808ce44"
    }
  },
  {
    "ts": null,
    "headline": "PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery",
    "summary": "NEW YORK & TOKYO, August 12, 2025--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, \"Astellas\") today announced positive topline results from the Phase 3 EV-303 clinical trial (also known as KEYNOTE-905). The EV-303 study is evaluating PADCEV™ (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with KEYTRUDA™ (pembrolizumab), a PD-1 inhibitor, as neoadjuvant and adjuvant treatment (before and after surgery) versus surger",
    "url": "https://finnhub.io/api/news?id=83e43a8fb53e74d57eaca6e72cf462ef320b46d8e3a10d310986d46160980737",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754991000,
      "headline": "PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery",
      "id": 136316183,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK & TOKYO, August 12, 2025--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, \"Astellas\") today announced positive topline results from the Phase 3 EV-303 clinical trial (also known as KEYNOTE-905). The EV-303 study is evaluating PADCEV™ (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with KEYTRUDA™ (pembrolizumab), a PD-1 inhibitor, as neoadjuvant and adjuvant treatment (before and after surgery) versus surger",
      "url": "https://finnhub.io/api/news?id=83e43a8fb53e74d57eaca6e72cf462ef320b46d8e3a10d310986d46160980737"
    }
  },
  {
    "ts": null,
    "headline": "Merck, Pfizer, Astellas Drug Combo Hits Key Goals in Bladder Cancer",
    "summary": "Merck, Pfizer, Astellas Drug Combo Hits Key Goals in Bladder Cancer",
    "url": "https://finnhub.io/api/news?id=dc65ae83c1a5efb04c24fb802e3932778cb143c9644f51a4bff8f7c3ab0d7c0f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754984160,
      "headline": "Merck, Pfizer, Astellas Drug Combo Hits Key Goals in Bladder Cancer",
      "id": 136331957,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Merck, Pfizer, Astellas Drug Combo Hits Key Goals in Bladder Cancer",
      "url": "https://finnhub.io/api/news?id=dc65ae83c1a5efb04c24fb802e3932778cb143c9644f51a4bff8f7c3ab0d7c0f"
    }
  },
  {
    "ts": null,
    "headline": "If You'd Invested $1,000 in Pfizer (PFE) Stock 3 Years Ago, Here's How Much You'd Have Today",
    "summary": "Investing is about looking ahead.",
    "url": "https://finnhub.io/api/news?id=90ab588c57d2dbc327b6a7e8b9b78710122a1202d8783848ba5bfd9861ad7677",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754961360,
      "headline": "If You'd Invested $1,000 in Pfizer (PFE) Stock 3 Years Ago, Here's How Much You'd Have Today",
      "id": 136316184,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Investing is about looking ahead.",
      "url": "https://finnhub.io/api/news?id=90ab588c57d2dbc327b6a7e8b9b78710122a1202d8783848ba5bfd9861ad7677"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Reports Positive Topline Phase 3 Results For HYMPAVZI™ In Hemophilia A or B With Inhibitors",
    "summary": "Pfizer Inc. (NYSE:PFE) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Pfizer Inc. (NYSE:PFE) reported positive topline results from its Phase 3 BASIS study, which evaluated HYMPAVZI™ (marstacimab) in patients with hemophilia A or B with inhibitors. The annualized bleeding rate was reduced by 93% with once-weekly subcutaneous medication as […]",
    "url": "https://finnhub.io/api/news?id=6a6b1e3b69310e1c3bf3525f4788126b8d5848604c9a1f6b0c4b464d14d703e5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754957944,
      "headline": "Pfizer Reports Positive Topline Phase 3 Results For HYMPAVZI™ In Hemophilia A or B With Inhibitors",
      "id": 136316185,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Pfizer Inc. (NYSE:PFE) reported positive topline results from its Phase 3 BASIS study, which evaluated HYMPAVZI™ (marstacimab) in patients with hemophilia A or B with inhibitors. The annualized bleeding rate was reduced by 93% with once-weekly subcutaneous medication as […]",
      "url": "https://finnhub.io/api/news?id=6a6b1e3b69310e1c3bf3525f4788126b8d5848604c9a1f6b0c4b464d14d703e5"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Just Beat Its Earning Estimates. Is This the Beginning of a Turnaround for the Pharmaceutical Stock?",
    "summary": "It was a rare breath of fresh air for shareholders.",
    "url": "https://finnhub.io/api/news?id=440fad085cf53a8790a8af52af9f5736b855cd944afaef7eea3803fcb1e30bbe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754957700,
      "headline": "Pfizer Just Beat Its Earning Estimates. Is This the Beginning of a Turnaround for the Pharmaceutical Stock?",
      "id": 136316186,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "It was a rare breath of fresh air for shareholders.",
      "url": "https://finnhub.io/api/news?id=440fad085cf53a8790a8af52af9f5736b855cd944afaef7eea3803fcb1e30bbe"
    }
  }
]